Legal Clouds Loom as Expansion Continues
The expansion effort comes at a turbulent time. Hims & Hers is currently locked in litigation with Danish drugmaker Novo Nordisk, following regulatory scrutiny tied to weight-loss treatments.
The dispute arose after a crackdown from the U.S. Food and Drug Administration forced Hims & Hers to abruptly withdraw its newly launched $49 copy of Novo Nordisk’s blockbuster weight-loss drug, Wegovy. The legal fight adds a layer of complexity as the company simultaneously presses forward with international growth.
Deal Terms and Timeline
The acquisition is expected to close in the middle of calendar year 2026, subject to customary conditions.
Hims & Hers said approximately $240 million of the purchase price will be paid in cash at closing, with the remainder structured in accordance with the transaction’s terms, bringing the total deal value to as much as $1.15 billion.
As digital health platforms race to capture global demand, the acquisition underscores an industry in motion — where borders blur, patients click instead of queue, and telehealth giants move swiftly to claim new ground.
